Among the more novel anti-cancer agents to emerge in recent years are those that prevent cancer cell proliferation and angiogenesis via “selective” targeted tyrosine kinase and vascular endothelial growth factor receptor (VEGFR) inhibition. The gene discussed is KDR; the disease is cancer.